Zymeworks Inc. (ZYME) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $21.96 (-3.30%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 17, 2025 | Asthika Goonewardene | Truist Financial | $40.00 | +82.1% |
| Nov 19, 2025 | Eva Verdejo | Wells Fargo | $25.00 | +13.8% |
| Nov 19, 2025 | Stephen Willey | Stifel Nicolaus | $40.00 | +82.1% |
| Nov 17, 2025 | Andrew Berens | Leerink Partners | $37.00 | +68.5% |
| Oct 14, 2025 | Robert Burns | H.C. Wainwright | $26.00 | +18.4% |
| Nov 21, 2024 | Andrew Berens | Leerink Partners | $26.00 | +18.4% |
| Nov 1, 2024 | Derek Archila | Wells Fargo | $12.00 | -45.4% |
| Oct 28, 2024 | Stephen Willey | Stifel Nicolaus | $28.00 | +27.5% |
| Sep 25, 2024 | Robert Burns | H.C. Wainwright | $12.00 | -45.4% |
| Sep 18, 2024 | Andrew Berens | H.C. Wainwright | $10.00 | -54.5% |
| Sep 10, 2024 | Stephen Willey | Stifel Nicolaus | $21.00 | -4.4% |
| Dec 19, 2022 | Akash Tewari | Jefferies | $11.00 | -49.9% |
| Nov 1, 2022 | Robert Burns | H.C. Wainwright | $8.00 | -63.6% |
| Sep 20, 2021 | Robert Burns | H.C. Wainwright | $44.00 | +100.4% |
Top Analysts Covering ZYME
ZYME vs Sector & Market
| Metric | ZYME | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +84.4% | +16316.1% | +17.1% |
| P/E Ratio | -25.95 | 3.03 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $10M | $83M | $172M | 4 |
| 2026-12-31 | $8M | $71M | $146M | 5 |
| 2027-03-31 | $6M | $51M | $105M | 3 |
| 2027-06-30 | $6M | $53M | $109M | 3 |
| 2027-09-30 | $6M | $55M | $113M | 3 |
| 2027-12-31 | $7M | $58M | $119M | 3 |
| 2028-12-31 | $184M | $184M | $184M | 8 |
| 2029-12-31 | $125M | $295M | $497M | 7 |
| 2030-12-31 | $166M | $392M | $660M | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $-0.14 | $0.90 | $2.13 | 3 |
| 2026-12-31 | $-0.10 | $0.67 | $1.59 | 4 |
| 2027-03-31 | $-0.01 | $0.05 | $0.12 | 2 |
| 2027-06-30 | $-0.01 | $0.08 | $0.19 | 2 |
| 2027-09-30 | $-0.01 | $0.08 | $0.19 | 2 |
| 2027-12-31 | $-0.02 | $0.13 | $0.31 | 2 |
| 2028-12-31 | $-0.26 | $0.03 | $0.34 | 6 |
| 2029-12-31 | $0.15 | $0.58 | $1.10 | 4 |
| 2030-12-31 | $0.23 | $0.92 | $1.74 | 2 |
Frequently Asked Questions
What is the analyst consensus for ZYME?
The consensus among 8 analysts covering Zymeworks Inc. (ZYME) is Buy with an average price target of $40.50.
What is the highest price target for ZYME?
The highest price target for ZYME is $44.00, set by Robert Burns at H.C. Wainwright on 2021-09-20.
What is the lowest price target for ZYME?
The lowest price target for ZYME is $8.00, set by Robert Burns at H.C. Wainwright on 2022-11-01.
How many analysts cover ZYME?
8 analysts have issued ratings for Zymeworks Inc. in the past 12 months.
Is ZYME a buy or sell right now?
Based on 8 analyst ratings, ZYME has a consensus rating of Buy (2.00/5) with a +84.4% upside to the consensus target of $40.50.
What are the earnings estimates for ZYME?
Analysts estimate ZYME will report EPS of $0.90 for the period ending 2026-09-30, with revenue estimated at $83M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.